GADOLIN: PRIMARY RESULTS FROM A PHASE III STUDY OF OBINUTUZUMAB PLUS BENDAMUSTINE COMPARED WITH BENDAMUSTINE ALONE IN PATIENTS WITH RITUXIMAB-REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA

被引：0
|
作者：
Sehn, L. [1 ,2 ]
Chua, N. [3 ]
Mayer, J. [4 ]
Dueck, G. [5 ]
Trneny, M. [6 ]
Bouabdallah, K. [7 ]
Fowler, N. [8 ]
Delwail, V. [9 ]
Press, O. [10 ]
Salles, G. [11 ]
Gribben, J. [12 ]
Lennard, A. [3 ]
Lugtenburg, P. [13 ]
Franklin, N. [14 ]
Wassner-Fritsch, E. [15 ]
Fingerle-Rowson, G. [15 ]
Cheson, B. [16 ]
机构：
[1] British Columbia Canc Agcy, Vancouver, BC V5Z 4E6, Canada
[2] Univ British Columbia, Vancouver, BC V5Z 1M9, Canada
[3] Univ Alberta, Cross Canc Inst, Edmonton, AB, Canada
[4] Brno & Masaryk Univ, Univ Hosp, Brno, Czech Republic
[5] BC Canc Agcy, Kelowna, Kelowna, BC, Canada
[6] Charles Univ Prague, Gen Hosp, Prague, Czech Republic
[7] CHU Haut Leveque, Pessac, France
[8] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA
[9] Univ Hosp, INSERM, Poitiers, France
[10] Fred Hutchinson Canc Res Ctr, Seattle, WA 98104 USA
[11] Hosp Civils Lyon, Pierre Benite, France
[12] Queen Mary Univ London, Barts Canc Inst, London, England
[13] Erasmus MC Canc Inst, Rotterdam, Netherlands
[14] F Hoffmann La Roche Ltd, Welwyn Garden City, Herts, England
[15] F Hoffmann La Roche Ltd, Basel, Switzerland
[16] Georgetown Univ Hosp, Washington, DC 20007 USA
来源：
HAEMATOLOGICA | 2015年 / 100卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
LB691
引用
收藏
页码：273 / 273
页数：1
相关论文
共 50 条
  • [21] Efficacy of bendamustine in rituximab-refractory indolent B-cell non-Hodgkin lymphoma: review of a pivotal trial
    Ujjani, Chaitra
    Cheson, Bruce
    FUTURE ONCOLOGY, 2011, 7 (01) : 9 - 14
  • [22] Bendamustine for the Treatment of Chronic Lymphocytic Leukemia and Rituximab-Refractory, Indolent B-Cell Non-Hodgkin Lymphoma
    Dennie, Trevor W.
    Kolesar, Jill M.
    CLINICAL THERAPEUTICS, 2009, 31 : 2290 - 2311
  • [23] Interest of the obinutuzumab (GA101) in combination with chemotherapy in refractory indolent non-Hodgkin's lymphoma to rituximab: results of the Phase III Gadolin
    Philippe, Laure
    HEMATOLOGIE, 2016, 22 (05): : 311 - +
  • [24] Phase II results of bendamustine in combination with rituximab in relapsed indolent non-Hodgkin's lymphoma
    van der Jagt, Richard H.
    Cohen, Philip
    Cheson, Bruce D.
    Tulpule, Anil
    Herst, Jordan A.
    Lemieux, Bernard
    Schwartzberg, Lee S.
    Robinson, K. Sue
    Oliver, Jennifer W.
    Williams, Michael E.
    ANNALS OF ONCOLOGY, 2006, 17 : 200 - 200
  • [25] Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway
    Fredrik Salvesen Haukaas
    Audun Ohna
    Tania Krivasi
    Applied Health Economics and Health Policy, 2018, 16 : 569 - 577
  • [26] Cost-Effectiveness of Obinutuzumab in Combination with Bendamustine Followed by Obinutuzumab Maintenance versus Bendamustine Alone in Treatment of Patients with Rituximab-Refractory Follicular Lymphoma in Norway
    Haukaas, Fredrik Salvesen
    Ohna, Audun
    Krivasi, Tania
    APPLIED HEALTH ECONOMICS AND HEALTH POLICY, 2018, 16 (04) : 569 - 577
  • [27] Combinations of idelalisib with rituximab and/or bendamustine in patients with recurrent indolent non-Hodgkin lymphoma
    de Vos, Sven
    Wagner-Johnston, Nina D.
    Coutre, Steven E.
    Flinn, Ian W.
    Schreeder, Marshall T.
    Fowler, Nathan H.
    Sharman, Jeff P.
    Boccia, Ralph V.
    Barrientos, Jacqueline C.
    Rai, Kanti R.
    Boyd, Thomas E.
    Furman, Richard R.
    Kim, Yeonhee
    Godfrey, Wayne R.
    Leonard, John P.
    BLOOD ADVANCES, 2016, 1 (02) : 122 - 131
  • [28] The combination of bendamustine, bortezomib, and rituximab for patients with relapsed/refractory indolent and mantle cell non-Hodgkin lymphoma
    Friedberg, Jonathan W.
    Vose, Julie M.
    Kelly, Jennifer L.
    Young, Faith
    Bernstein, Steven H.
    Peterson, Derick
    Rich, Lynn
    Blumel, Susan
    Proia, Nicole K.
    Liesveld, Jane
    Fisher, Richard I.
    Armitage, James O.
    Grant, Steven
    Leonard, John P.
    BLOOD, 2011, 117 (10) : 2807 - 2812
  • [29] Pharmacokinetics of Bendamustine Hydrochloride in Chinese Patients with Indolent Non-Hodgkin Lymphoma (iNHL) Refractory to Rituximab Treatment
    Han, Xiaohong
    Li, Ning
    Song, Yuan-Yuan
    Hellriegel, Edward
    Robertson, Philmore
    Shi, Yuan-Kai
    BLOOD, 2016, 128 (22)
  • [30] Bendamustine in patients with rituximab-refractory indolent and transformed non-hodgkin's lymphoma: Results from a phase II multicenter, single-agent study (vol 26, pg 204, 2008)
    Friedberg
    JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (11) : 1911 - 1911
12345